Connect with us

Business

Sanofi-GlaxoSmithKline Covid Vaccine Shows Promise, Firm Says – The New York Times

A Phase 3 trial will start in the coming weeks. The drug makers expect their shot will become available in the last three months of this year.

Published

on

Article feature image
ADVERTISEMENT

Sanofi announced the findings in a statement and said it plans to soon publish the results in a medical journal.
Sanofi and GSK are much more experienced in vaccine development than a number of their rivals that have already won authorization. The two companies used a more established approach than those deployed in other, more swiftly developed Covid vaccines. Their shot is based on viral proteins produced with engineered viruses that grow inside insect cells. GSK is supplying the Sanofi vaccine…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
JetBlue, Southwest, Delta, and others sued by man over mask mandates – Business Insider
Article feature image
Elephant in the housing market is a win for builders – Fox Business
Article feature image
NASA ‘keeping eye’ on Jeff Bezos and other space astronaut billionaires – Fox Business